Ung thư dạ dày, Phiên bản 2.2022, Hướng dẫn Thực hành Lâm sàng của NCCN trong Ung thư học

Ma, 2016, Lauren classification and individualized chemotherapy in gastric cancer, Oncol Lett, 11, 2959, 10.3892/ol.2016.4337

Bergquist, 2019, Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features, Surgery, 166, 547, 10.1016/j.surg.2019.04.036

Maugeri-Saccà, 2013, FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort, J Exp Clin Cancer Res, 32, 67, 10.1186/1756-9966-32-67

Torre, 2016, Global cancer incidence and mortality rates and trends-an update, Cancer Epidemiol Biomarkers Prev, 25, 16, 10.1158/1055-9965.EPI-15-0578

Hechtman, 2012, HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications, Arch Pathol Lab Med, 136, 691, 10.5858/arpa.2011-0168-RS

Rivera, 2019, Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial, Cancer Chemother Pharmacol, 83, 1175, 10.1007/s00280-019-03820-7

Matsumoto, 2000, Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer, J Gastroenterol, 35, 326, 10.1007/s005350050356

Deng, 2021, Alcohol consumption and risk of stomach cancer: a meta-analysis, Chem Biol Interact, 336, 109365, 10.1016/j.cbi.2021.109365

MacLeod, 1949, The clinical evaluation of chemotherapeutic agents in cancer, Evaluation of Chemotherapeutic Agents

Moehler, 2003, Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer, Anticancer Drugs, 14, 645, 10.1097/00001813-200309000-00010

Soularue, 2015, Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study, Bull Cancer, 102, 324, 10.1016/j.bulcan.2014.08.001

Poultsides, 2008, Angiographic embolization for gastroduodenal hemorrhage: safety, efficacy, and predictors of outcome, Arch Surg, 143, 457, 10.1001/archsurg.143.5.457

Al-Batran, 2004, Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer, J Clin Oncol, 22, 658, 10.1200/JCO.2004.07.042

Ajani, 2005, Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma, J Clin Oncol, 23, 5660, 10.1200/JCO.2005.17.376

Cardoso, 2012, A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer, Gastric Cancer, 15, S19, 10.1007/s10120-011-0115-4

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Fuchs, 2003, Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer, J Clin Oncol, 21, 807, 10.1200/JCO.2003.08.058

Sano, 2017, Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project, Gastric Cancer, 20, 217, 10.1007/s10120-016-0601-9

Ajani, 2002, CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study, Cancer, 94, 641, 10.1002/cncr.10279

Shitara, 2018, Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1437, 10.1016/S1470-2045(18)30739-3

Abdalla, 2004, Staging and preoperative evaluation of upper gastrointestinal malignancies, Semin Oncol, 31, 513, 10.1053/j.seminoncol.2004.04.014

Van Cutsem, 2015, Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study, Ann Oncol, 26, 149, 10.1093/annonc/mdu496

Louvet, 2002, Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients, J Clin Oncol, 20, 4543, 10.1200/JCO.2002.02.021

Sym, 2013, A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy, Cancer Chemother Pharmacol, 71, 481, 10.1007/s00280-012-2027-3

Ly, 2010, A systematic review of methods to palliate malignant gastric outlet obstruction, Surg Endosc, 24, 290, 10.1007/s00464-009-0577-1

Wang, 2017, Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies, Oncotarget, 8, 99013, 10.18632/oncotarget.20918

Arnold, 2019, Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry, Pathol Res Pract, 215, 152662, 10.1016/j.prp.2019.152662

Glimelius, 1997, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer, Ann Oncol, 8, 163, 10.1023/A:1008243606668

Dank, 2008, Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 19, 1450, 10.1093/annonc/mdn166

Burtness, 2009, Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer, Ann Oncol, 20, 1242, 10.1093/annonc/mdn787

Oaknin, 2020, Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial, JAMA Oncol, 6, 1766, 10.1001/jamaoncol.2020.4515

Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169

Ilson, 2007, Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer, Ann Oncol, 18, 898, 10.1093/annonc/mdm004

Torre, 2016, Global cancer incidence and mortality rates and trends-an update, Cancer Epidemiol Biomarkers Prev, 25, 16, 10.1158/1055-9965.EPI-15-0578

Issaka, 2014, Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction, Surg Endosc, 28, 1668, 10.1007/s00464-013-3368-7

Klempner, 2019, Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis, Oncologist, 24, 475, 10.1634/theoncologist.2018-0602

Ilson, 2019, Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial, JAMA Oncol, 6, e193531, 10.1001/jamaoncol.2019.3531

Fuchs, 2019, Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 420, 10.1016/S1470-2045(18)30791-5

Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X

Lim, 2006, CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy, Radiographics, 26, 143, 10.1148/rg.261055078

Etemadi, 2020, The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017, Lancet Gastroenterol Hepatol, 5, 42, 10.1016/S2468-1253(19)30328-0

Kang, 2009, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 20, 666, 10.1093/annonc/mdn717

Zhao, 2017, Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China, Eur J Cancer Prev, 26, 357, 10.1097/CEJ.0000000000000262

Huang, 2018, The 8th edition American Joint Committee on gastric cancer pathological staging classification performs well in a population with high proportion of locally advanced disease, Eur J Surg Oncol, 44, 1634, 10.1016/j.ejso.2018.05.036

Rosenbaum, 2006, Staging and follow-up of gastrointestinal tumors with PET/CT, Abdom Imaging, 31, 25, 10.1007/s00261-005-0031-3

Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9

Falk, 2007, Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences, Acta Oncol, 46, 1070, 10.1080/02841860701403046

Kang, 2012, Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone, J Clin Oncol, 30, 1513, 10.1200/JCO.2011.39.4585

Brell, 2009, A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma, Cancer Chemother Pharmacol, 63, 851, 10.1007/s00280-008-0807-6

Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial, JAMA Oncol, 4, e180013, 10.1001/jamaoncol.2018.0013

Spolverato, 2015, Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative, J Am Coll Surg, 220, 48, 10.1016/j.jamcollsurg.2014.06.023

Brar, 2014, Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel, JAMA Surg, 149, 18, 10.1001/jamasurg.2013.3959

Ilson, 2019, Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial, JAMA Oncol, 6, e193531, 10.1001/jamaoncol.2019.3531

Cho, 2017, Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer, World J Gastroenterol, 23, 7407, 10.3748/wjg.v23.i41.7407

Tabernero, 2017, Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment of advanced gastric or gastroesophageal junction cancer, Mol Cancer Ther, 16, 2215, 10.1158/1535-7163.MCT-16-0895

Al-Batran, 2013, The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+), Eur J Cancer, 49, 835, 10.1016/j.ejca.2012.09.025

Janjigian, 2021, First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial, Lancet, 398, 27, 10.1016/S0140-6736(21)00797-2

Okines, 2009, Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann Oncol, 20, 1529, 10.1093/annonc/mdp047

Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014

Okines, 2009, Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann Oncol, 20, 1529, 10.1093/annonc/mdp047

Ilson, 2004, Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer, Oncology (Williston Park), 18, 22

Kondoh, 2015, Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study, BMC Palliat Care, 14, 37, 10.1186/s12904-015-0034-y

Wang, 2019, Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials, Int J Clin Oncol, 24, 614, 10.1007/s10147-019-01425-x

Sakai, 2018, An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial), J Clin Oncol, 36, TPS4138, 10.1200/JCO.2018.36.15_suppl.TPS4138

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Lindsay, 2004, Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass, Aliment Pharmacol Ther, 19, 901, 10.1111/j.1365-2036.2004.01896.x

Ilson, 2004, Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer, Oncology (Williston Park), 18, 22

Louvet, 2002, Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients, J Clin Oncol, 20, 4543, 10.1200/JCO.2002.02.021

Jørgensen, 2012, HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature, J Cancer, 3, 137, 10.7150/jca.4090

Lim, 2007, Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?, J Surg Oncol, 95, 118, 10.1002/jso.20328

Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448

Pozzo, 2004, Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study, Ann Oncol, 15, 1773, 10.1093/annonc/mdh473

Falk, 2007, Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences, Acta Oncol, 46, 1070, 10.1080/02841860701403046

Ilson, 2007, Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer, Ann Oncol, 18, 898, 10.1093/annonc/mdm004

Amin, 2017, AJCC cancer staging manual, 10.1007/978-3-319-40618-3

Enzinger, 2005, A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma, Dig Dis Sci, 50, 2218, 10.1007/s10620-005-3038-2

Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429

Maugeri-Saccà, 2013, FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort, J Exp Clin Cancer Res, 32, 67, 10.1186/1756-9966-32-67

Ajani, 1994, Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus, J Natl Cancer Inst, 86, 1086, 10.1093/jnci/86.14.1086

Yan, 2010, A study of HER2 gene amplification and protein expression in gastric cancer, J Clin Pathol, 63, 839, 10.1136/jcp.2010.076570

Roth, 2007, Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research, J Clin Oncol, 25, 3217, 10.1200/JCO.2006.08.0135

Albertsson, 2007, Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer, Med Oncol, 24, 407, 10.1007/s12032-007-0028-6

Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169

Silas, 2005, Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: a comparison of indications, complications and outcomes in 370 patients, Eur J Radiol, 56, 84, 10.1016/j.ejrad.2005.02.007

Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200/JCO.1984.2.3.187

Berton, 2021, Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study, J Clin Oncol, 39, 2564, 10.1200/JCO.2021.39.15_suppl.2564

Rüdiger Siewert, 2000, Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients, Ann Surg, 232, 353, 10.1097/00000658-200009000-00007

Holt, 2004, Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice?, Gastrointest Endosc, 60, 1010, 10.1016/S0016-5107(04)02276-X

Stahl, 2003, FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings, Eur J Nucl Med Mol Imaging, 30, 288, 10.1007/s00259-002-1029-5

Lee, 1991, Malignant small bowel obstruction and ascites: not a contraindication to percutaneous gastrostomy, Clin Radiol, 44, 332, 10.1016/S0009-9260(05)81270-X

Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429

Makiyama, 2020, Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study), J Clin Oncol, 38, 1919, 10.1200/JCO.19.03077

Kim, 2007, Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer, World J Gastroenterol, 13, 916, 10.3748/wjg.v13.i6.916

Enzinger, 2009, Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer, Ann Oncol, 20, 475, 10.1093/annonc/mdn658

Kim, 2018, HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study, Appl Immunohistochem Mol Morphol, 26, 239, 10.1097/PAI.0000000000000423

Di Lauro, 2014, Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer, Gastric Cancer, 17, 718, 10.1007/s10120-013-0321-3

Inal, 2012, Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution, Neoplasma, 59, 233, 10.4149/neo_2012_030

Stahl, 2003, FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings, Eur J Nucl Med Mol Imaging, 30, 288, 10.1007/s00259-002-1029-5

Siewert, 1996, Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection, Dis Esophagus, 9, 173

Lorenzen, 2009, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 20, 1667, 10.1093/annonc/mdp069

Klempner, 2019, Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis, Oncologist, 24, 475, 10.1634/theoncologist.2018-0602

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492

Yusefi, 2018, Risk factors for gastric cancer: a systematic review, Asian Pac J Cancer Prev, 19, 591

Van Cutsem, 2015, HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer, Gastric Cancer, 18, 476, 10.1007/s10120-014-0402-y

Enzinger, 2016, CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers, J Clin Oncol, 34, 2736, 10.1200/JCO.2015.65.5092

Berton, 2021, Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study, J Clin Oncol, 39, 2564, 10.1200/JCO.2021.39.15_suppl.2564

Spolverato, 2015, Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative, J Am Coll Surg, 220, 48, 10.1016/j.jamcollsurg.2014.06.023

Kim, 2008, Clinical benefit of palliative radiation therapy in advanced gastric cancer, Acta Oncol, 47, 421, 10.1080/02841860701621233

Karimi, 2014, Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention, Cancer Epidemiol Biomarkers Prev, 23, 700, 10.1158/1055-9965.EPI-13-1057

Janjigian, 2021, First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial, Lancet, 398, 27, 10.1016/S0140-6736(21)00797-2

Ajani, 2005, Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma, J Clin Oncol, 23, 5660, 10.1200/JCO.2005.17.376

Petrasch, 1998, Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer, Br J Cancer, 78, 511, 10.1038/bjc.1998.524

Mezhir, 2010, Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients, Ann Surg Oncol, 17, 3173, 10.1245/s10434-010-1183-0

Karimi, 2014, Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention, Cancer Epidemiol Biomarkers Prev, 23, 700, 10.1158/1055-9965.EPI-13-1057

Albertsson, 2007, Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer, Med Oncol, 24, 407, 10.1007/s12032-007-0028-6

Siegel, 2021, Cancer statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654

Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J Clin Oncol, 38, 1, 10.1200/JCO.19.02105

Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002

Hu, 2012, Gastric cancer: classification, histology and application of molecular pathology, J Gastrointest Oncol, 3, 251

Kunz, 2012, HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment, Appl Immunohistochem Mol Morphol, 20, 13, 10.1097/PAI.0b013e31821c821c

Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x

Al-Batran, 2008, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 26, 1435, 10.1200/JCO.2007.13.9378

Chau, 2004, Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer─pooled analysis from three multicenter, randomized, controlled trials using individual patient data, J Clin Oncol, 22, 2395, 10.1200/JCO.2004.08.154

Lim, 2006, CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy, Radiographics, 26, 143, 10.1148/rg.261055078

De Andrade, 2014, The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review, J Surg Oncol, 110, 291, 10.1002/jso.23632

Endo, 2014, Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: a prospective multicenter study, J Surg Oncol, 109, 208, 10.1002/jso.23486

Mezhir, 2010, Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients, Ann Surg Oncol, 17, 3173, 10.1245/s10434-010-1183-0

Hong, 2004, A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer, Ann Oncol, 15, 1344, 10.1093/annonc/mdh343

Zhao, 2017, Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China, Eur J Cancer Prev, 26, 357, 10.1097/CEJ.0000000000000262

Bando, 2019, Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer, Gastric Cancer, 22, 123, 10.1007/s10120-018-0799-9

Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130

Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002

Al-Batran, 2008, Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 19, 1882, 10.1093/annonc/mdn403

Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial, JAMA Oncol, 4, e180013, 10.1001/jamaoncol.2018.0013

Beretta, 2006, Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition, Tumori, 92, 379, 10.1177/030089160609200502

Ajani, 1994, Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus, J Natl Cancer Inst, 86, 1086, 10.1093/jnci/86.14.1086

Hechtman, 2012, HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications, Arch Pathol Lab Med, 136, 691, 10.5858/arpa.2011-0168-RS

Kim, 2018, HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study, Appl Immunohistochem Mol Morphol, 26, 239, 10.1097/PAI.0000000000000423

Holt, 2004, Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice?, Gastrointest Endosc, 60, 1010, 10.1016/S0016-5107(04)02276-X

Murphy, 2006, Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers, J Mol Diagn, 8, 305, 10.2353/jmoldx.2006.050092

Lustberg, 2010, Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma, J Thorac Oncol, 5, 713, 10.1097/JTO.0b013e3181d7776d

Powell, 2002, Continuing rising trend in oesophageal adenocarcinoma, Int J Cancer, 102, 422, 10.1002/ijc.10721

Ryan, 1998, Performing radiologic gastrostomy or gastrojejunostomy in patients with malignant ascites, AJR Am J Roentgenol, 171, 1003, 10.2214/ajr.171.4.9762985

Park, 2008, Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer, Cancer Chemother Pharmacol, 61, 623, 10.1007/s00280-007-0515-7

Willis, 2019, Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel, Clin Cancer Res, 25, 7035, 10.1158/1078-0432.CCR-19-1324

Kim, 2008, Clinical benefit of palliative radiation therapy in advanced gastric cancer, Acta Oncol, 47, 421, 10.1080/02841860701621233

Chau, 2004, Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer─pooled analysis from three multicenter, randomized, controlled trials using individual patient data, J Clin Oncol, 22, 2395, 10.1200/JCO.2004.08.154

Tabernero, 2017, Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment of advanced gastric or gastroesophageal junction cancer, Mol Cancer Ther, 16, 2215, 10.1158/1535-7163.MCT-16-0895

Moehler, 2010, A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 21, 71, 10.1093/annonc/mdp269

Ilson, 2000, A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus, Cancer J, 6, 316

Luo, 2010, Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer, Chemotherapy, 56, 94, 10.1159/000305256

Issaka, 2014, Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction, Surg Endosc, 28, 1668, 10.1007/s00464-013-3368-7

Janjigian, 2012, Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis, Ann Oncol, 23, 2656, 10.1093/annonc/mds104

Chua, 2012, Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review, Int J Cancer, 130, 2845, 10.1002/ijc.26292

Shinozaki-Ushiku, 2020, The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion, Gastric Cancer, 23, 944, 10.1007/s10120-020-01061-9

Park, 2008, Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer, Cancer Chemother Pharmacol, 61, 623, 10.1007/s00280-007-0515-7

Dank, 2008, Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 19, 1450, 10.1093/annonc/mdn166

Imbesi, 2005, A multidisciplinary approach to gastrointestinal bleeding in cancer patients, J Support Oncol, 3, 101

Tramacere, 2012, A meta-analysis on alcohol drinking and gastric cancer risk, Ann Oncol, 23, 28, 10.1093/annonc/mdr135

Kim, 2012, A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer, Eur J Cancer, 48, 518, 10.1016/j.ejca.2011.12.017

Arnold, 2019, Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry, Pathol Res Pract, 215, 152662, 10.1016/j.prp.2019.152662

Sano, 2017, Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project, Gastric Cancer, 20, 217, 10.1007/s10120-016-0601-9

Wieder, 2011, PET and PET-CT in esophageal and gastric cancer, Methods Mol Biol, 727, 59, 10.1007/978-1-61779-062-1_5

Willis, 2019, Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel, Clin Cancer Res, 25, 7035, 10.1158/1078-0432.CCR-19-1324

Sym, 2013, A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy, Cancer Chemother Pharmacol, 71, 481, 10.1007/s00280-012-2027-3

Shitara, 2018, Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1437, 10.1016/S1470-2045(18)30739-3

Assersohn, 2004, Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, Ann Oncol, 15, 64, 10.1093/annonc/mdh007

Kim, 2010, A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer, Cancer Chemother Pharmacol, 66, 31, 10.1007/s00280-009-1130-6

In, 2017, Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Database, Ann Surg Oncol, 24, 3683, 10.1245/s10434-017-6078-x

Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448

Matsumoto, 2000, Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer, J Gastroenterol, 35, 326, 10.1007/s005350050356

Sheibani, 2013, Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy, Aliment Pharmacol Ther, 38, 144, 10.1111/apt.12347

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014

Glimelius, 1997, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer, Ann Oncol, 8, 163, 10.1023/A:1008243606668

Al-Batran, 2008, Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 19, 1882, 10.1093/annonc/mdn403

Kwee, 2007, Imaging in local staging of gastric cancer: a systematic review, J Clin Oncol, 25, 2107, 10.1200/JCO.2006.09.5224

Shitara, 2019, Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): subgroup analysis from TAGS, J Clin Oncol, 37, 4037, 10.1200/JCO.2019.37.15_suppl.4037

Imbesi, 2005, A multidisciplinary approach to gastrointestinal bleeding in cancer patients, J Support Oncol, 3, 101

Yan, 2010, A study of HER2 gene amplification and protein expression in gastric cancer, J Clin Pathol, 63, 839, 10.1136/jcp.2010.076570

Sarela, 2006, Selection of patients with gastric adenocarcinoma for laparoscopic staging, Am J Surg, 191, 134, 10.1016/j.amjsurg.2005.10.015

Dassen, 2009, FDG-PET has no definite role in preoperative imaging in gastric cancer, Eur J Surg Oncol, 35, 449, 10.1016/j.ejso.2008.11.010

Jeurnink, 2007, Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review, BMC Gastroenterol, 7, 18, 10.1186/1471-230X-7-18

Crew, 2006, Epidemiology of gastric cancer, World J Gastroenterol, 12, 354, 10.3748/wjg.v12.i3.354

Bentrem, 2005, The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection, Ann Surg Oncol, 12, 347, 10.1245/ASO.2005.03.065

Grabsch, 2010, HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series, Cell Oncol, 32, 57

Sheibani, 2013, Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy, Aliment Pharmacol Ther, 38, 144, 10.1111/apt.12347

Sarela, 2006, Selection of patients with gastric adenocarcinoma for laparoscopic staging, Am J Surg, 191, 134, 10.1016/j.amjsurg.2005.10.015

Kim, 2010, A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer, Cancer Chemother Pharmacol, 66, 31, 10.1007/s00280-009-1130-6

Lorenzen, 2009, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 20, 1667, 10.1093/annonc/mdp069

Kato, 2018, Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma, Clin Cancer Res, 24, 6248, 10.1158/1078-0432.CCR-18-1128

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492

Endo, 2014, Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: a prospective multicenter study, J Surg Oncol, 109, 208, 10.1002/jso.23486

Sitarz, 2018, Gastric cancer: epidemiology, prevention, classification, and treatment, Cancer Manag Res, 10, 239, 10.2147/CMAR.S149619

Kim, 2012, A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer, Eur J Cancer, 48, 518, 10.1016/j.ejca.2011.12.017

Hall, 2019, Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial, J Clin Oncol, 37, 4006, 10.1200/JCO.2019.37.15_suppl.4006

Makiyama, 2020, Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study), J Clin Oncol, 38, 1919, 10.1200/JCO.19.03077

Brar, 2014, Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel, JAMA Surg, 149, 18, 10.1001/jamasurg.2013.3959

Kim, 2007, Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer, World J Gastroenterol, 13, 916, 10.3748/wjg.v13.i6.916

Kwee, 2007, Imaging in local staging of gastric cancer: a systematic review, J Clin Oncol, 25, 2107, 10.1200/JCO.2006.09.5224

Al-Batran, 2013, The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+), Eur J Cancer, 49, 835, 10.1016/j.ejca.2012.09.025

Abdalla, 2004, Staging and preoperative evaluation of upper gastrointestinal malignancies, Semin Oncol, 31, 513, 10.1053/j.seminoncol.2004.04.014

He, 2017, Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies, Oncotarget, 8, 84459, 10.18632/oncotarget.20880

Moehler, 2005, Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer, Br J Cancer, 92, 2122, 10.1038/sj.bjc.6602649

Burtness, 2009, Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer, Ann Oncol, 20, 1242, 10.1093/annonc/mdn787

Amin, 2017, AJCC cancer staging manual, 10.1007/978-3-319-40618-3

Okamura, 2018, Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics, JCO Precis Oncol, 10.1200/PO.18.00183

Crew, 2006, Epidemiology of gastric cancer, World J Gastroenterol, 12, 354, 10.3748/wjg.v12.i3.354

Shah, 2015, Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium, J Clin Oncol, 33, 3874, 10.1200/JCO.2015.60.7465

Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x

Inal, 2012, Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution, Neoplasma, 59, 233, 10.4149/neo_2012_030

Shitara, 2020, Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, N Engl J Med, 382, 2419, 10.1056/NEJMoa2004413

Beretta, 2006, Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition, Tumori, 92, 379, 10.1177/030089160609200502

Sitarz, 2018, Gastric cancer: epidemiology, prevention, classification, and treatment, Cancer Manag Res, 10, 239, 10.2147/CMAR.S149619

Elsaid, 2005, Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer, J Clin Oncol, 23, 4014, 10.1200/jco.2005.23.16_suppl.4014

Rivera, 2019, Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial, Cancer Chemother Pharmacol, 83, 1175, 10.1007/s00280-019-03820-7

Silas, 2005, Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: a comparison of indications, complications and outcomes in 370 patients, Eur J Radiol, 56, 84, 10.1016/j.ejrad.2005.02.007

Wieder, 2011, PET and PET-CT in esophageal and gastric cancer, Methods Mol Biol, 727, 59, 10.1007/978-1-61779-062-1_5

Luo, 2010, Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer, Chemotherapy, 56, 94, 10.1159/000305256

Rosenbaum, 2006, Staging and follow-up of gastrointestinal tumors with PET/CT, Abdom Imaging, 31, 25, 10.1007/s00261-005-0031-3

Tanner, 2005, Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Ann Oncol, 16, 273, 10.1093/annonc/mdi064

Poultsides, 2008, Angiographic embolization for gastroduodenal hemorrhage: safety, efficacy, and predictors of outcome, Arch Surg, 143, 457, 10.1001/archsurg.143.5.457

Cho, 2017, Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer, World J Gastroenterol, 23, 7407, 10.3748/wjg.v23.i41.7407

Enzinger, 2016, CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers, J Clin Oncol, 34, 2736, 10.1200/JCO.2015.65.5092

Sym, 2008, Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane, Am J Clin Oncol, 31, 151, 10.1097/COC.0b013e31815878a2

Deng, 2021, Alcohol consumption and risk of stomach cancer: a meta-analysis, Chem Biol Interact, 336, 109365, 10.1016/j.cbi.2021.109365

Roth, 2007, Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research, J Clin Oncol, 25, 3217, 10.1200/JCO.2006.08.0135

Jørgensen, 2012, HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature, J Cancer, 3, 137, 10.7150/jca.4090

Weber, 2004, Imaging of esophageal and gastric cancer, Semin Oncol, 31, 530, 10.1053/j.seminoncol.2004.04.016

Doebele, 2020, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 271, 10.1016/S1470-2045(19)30691-6

Moehler, 2010, A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 21, 71, 10.1093/annonc/mdp269

Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130

Kim, 2015, Endoscopic management of tumor bleeding from inoperable gastric cancer, Clin Endosc, 48, 121, 10.5946/ce.2015.48.2.121

Hu, 2012, Gastric cancer: classification, histology and application of molecular pathology, J Gastrointest Oncol, 3, 251

Bartley, 2017, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology, J Clin Oncol, 35, 446, 10.1200/JCO.2016.69.4836

Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J Clin Oncol, 38, 1, 10.1200/JCO.19.02105

Bergquist, 2019, Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features, Surgery, 166, 547, 10.1016/j.surg.2019.04.036

Ford, 2014, Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial, Lancet Oncol, 15, 78, 10.1016/S1470-2045(13)70549-7

Chung, 2021, First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811, Future Oncol, 17, 491, 10.2217/fon-2020-0737

Gatalica, 2019, Molecular characterization of cancers with NTRK gene fusions, Mod Pathol, 32, 147, 10.1038/s41379-018-0118-3

Lustberg, 2010, Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma, J Thorac Oncol, 5, 713, 10.1097/JTO.0b013e3181d7776d

Chua, 2012, Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review, Int J Cancer, 130, 2845, 10.1002/ijc.26292

Van Cutsem, 2015, HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer, Gastric Cancer, 18, 476, 10.1007/s10120-014-0402-y

Kondoh, 2015, Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study, BMC Palliat Care, 14, 37, 10.1186/s12904-015-0034-y

Janjigian, 2012, Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis, Ann Oncol, 23, 2656, 10.1093/annonc/mds104

Chung, 2021, First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811, Future Oncol, 17, 491, 10.2217/fon-2020-0737

Shah, 2015, Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium, J Clin Oncol, 33, 3874, 10.1200/JCO.2015.60.7465

He, 2017, Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies, Oncotarget, 8, 84459, 10.18632/oncotarget.20880

Chen, 2005, Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography, Cancer, 103, 2383, 10.1002/cncr.21074

Cardoso, 2012, A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer, Gastric Cancer, 15, S19, 10.1007/s10120-011-0115-4

Assersohn, 2004, Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, Ann Oncol, 15, 64, 10.1093/annonc/mdh007

Tanner, 2005, Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Ann Oncol, 16, 273, 10.1093/annonc/mdi064

Dassen, 2009, FDG-PET has no definite role in preoperative imaging in gastric cancer, Eur J Surg Oncol, 35, 449, 10.1016/j.ejso.2008.11.010

Kim, 2015, Endoscopic management of tumor bleeding from inoperable gastric cancer, Clin Endosc, 48, 121, 10.5946/ce.2015.48.2.121

Shinozaki-Ushiku, 2020, The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion, Gastric Cancer, 23, 944, 10.1007/s10120-020-01061-9

Wang, 2019, Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials, Int J Clin Oncol, 24, 614, 10.1007/s10147-019-01425-x

Lee, 1991, Malignant small bowel obstruction and ascites: not a contraindication to percutaneous gastrostomy, Clin Radiol, 44, 332, 10.1016/S0009-9260(05)81270-X

Rüschoff, 2010, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 457, 299, 10.1007/s00428-010-0952-2

Karpeh, 2000, Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients, Ann Surg, 232, 362, 10.1097/00000658-200009000-00008

Sym, 2008, Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane, Am J Clin Oncol, 31, 151, 10.1097/COC.0b013e31815878a2

Sakai, 2018, An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial), J Clin Oncol, 36, TPS4138, 10.1200/JCO.2018.36.15_suppl.TPS4138

Gatalica, 2019, Molecular characterization of cancers with NTRK gene fusions, Mod Pathol, 32, 147, 10.1038/s41379-018-0118-3

Karpeh, 2000, Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients, Ann Surg, 232, 362, 10.1097/00000658-200009000-00008

Bando, 2019, Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer, Gastric Cancer, 22, 123, 10.1007/s10120-018-0799-9

Le, 2016, PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers, J Clin Oncol, 34, 195, 10.1200/jco.2016.34.4_suppl.195

Wang, 2017, Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies, Oncotarget, 8, 99013, 10.18632/oncotarget.20918

Jeurnink, 2010, Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial, Gastrointest Endosc, 71, 490, 10.1016/j.gie.2009.09.042

Wollman, 1997, Percutaneous radiologic and endoscopic gastrostomy: a 3-year institutional analysis of procedure performance, AJR Am J Roentgenol, 169, 1551, 10.2214/ajr.169.6.9393163

Chen, 2005, Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography, Cancer, 103, 2383, 10.1002/cncr.21074

Kato, 2018, Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma, Clin Cancer Res, 24, 6248, 10.1158/1078-0432.CCR-18-1128

Jeurnink, 2010, Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial, Gastrointest Endosc, 71, 490, 10.1016/j.gie.2009.09.042

Bartley, 2017, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology, J Clin Oncol, 35, 446, 10.1200/JCO.2016.69.4836

Tramacere, 2012, A meta-analysis on alcohol drinking and gastric cancer risk, Ann Oncol, 23, 28, 10.1093/annonc/mdr135

Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X

Soularue, 2015, Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study, Bull Cancer, 102, 324, 10.1016/j.bulcan.2014.08.001

Moehler, 2005, Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer, Br J Cancer, 92, 2122, 10.1038/sj.bjc.6602649

De Andrade, 2014, The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review, J Surg Oncol, 110, 291, 10.1002/jso.23632

Rüschoff, 2010, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 457, 299, 10.1007/s00428-010-0952-2

Jeurnink, 2007, Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review, BMC Gastroenterol, 7, 18, 10.1186/1471-230X-7-18

Oaknin, 2020, Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial, JAMA Oncol, 6, 1766, 10.1001/jamaoncol.2020.4515

Ilson, 2000, A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus, Cancer J, 6, 316

Le, 2016, PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers, J Clin Oncol, 34, 195, 10.1200/jco.2016.34.4_suppl.195

Okamura, 2018, Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics, JCO Precis Oncol, 10.1200/PO.18.00183

Yusefi, 2018, Risk factors for gastric cancer: a systematic review, Asian Pac J Cancer Prev, 19, 591

Tsendsuren, 2006, Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer, World J Gastroenterol, 12, 43, 10.3748/wjg.v12.i1.43

Powell, 2002, Continuing rising trend in oesophageal adenocarcinoma, Int J Cancer, 102, 422, 10.1002/ijc.10721

Pozzo, 2004, Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study, Ann Oncol, 15, 1773, 10.1093/annonc/mdh473

MacLeod, 1949, The clinical evaluation of chemotherapeutic agents in cancer, Evaluation of Chemotherapeutic Agents

Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9

Di Lauro, 2014, Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer, Gastric Cancer, 17, 718, 10.1007/s10120-013-0321-3

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

Wollman, 1997, Percutaneous radiologic and endoscopic gastrostomy: a 3-year institutional analysis of procedure performance, AJR Am J Roentgenol, 169, 1551, 10.2214/ajr.169.6.9393163

Wilke, 2014, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, Lancet Oncol, 15, 1224, 10.1016/S1470-2045(14)70420-6

Huang, 2018, The 8th edition American Joint Committee on gastric cancer pathological staging classification performs well in a population with high proportion of locally advanced disease, Eur J Surg Oncol, 44, 1634, 10.1016/j.ejso.2018.05.036

Murphy, 2006, Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers, J Mol Diagn, 8, 305, 10.2353/jmoldx.2006.050092

Al-Batran, 2008, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 26, 1435, 10.1200/JCO.2007.13.9378

Etemadi, 2020, The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017, Lancet Gastroenterol Hepatol, 5, 42, 10.1016/S2468-1253(19)30328-0

Petrasch, 1998, Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer, Br J Cancer, 78, 511, 10.1038/bjc.1998.524

Grabsch, 2010, HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series, Cell Oncol, 32, 57

Ford, 2014, Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial, Lancet Oncol, 15, 78, 10.1016/S1470-2045(13)70549-7

Gadgeel, 2003, Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer, Am J Clin Oncol, 26, 37, 10.1097/00000421-200302000-00008

Hall, 2019, Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial, J Clin Oncol, 37, 4006, 10.1200/JCO.2019.37.15_suppl.4006

Shitara, 2019, Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): subgroup analysis from TAGS, J Clin Oncol, 37, 4037, 10.1200/JCO.2019.37.15_suppl.4037

Moehler, 2003, Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer, Anticancer Drugs, 14, 645, 10.1097/00001813-200309000-00010

Ma, 2016, Lauren classification and individualized chemotherapy in gastric cancer, Oncol Lett, 11, 2959, 10.3892/ol.2016.4337

Tsendsuren, 2006, Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer, World J Gastroenterol, 12, 43, 10.3748/wjg.v12.i1.43

Elsaid, 2005, Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer, J Clin Oncol, 23, 4014, 10.1200/jco.2005.23.16_suppl.4014

Siegel, 2021, Cancer statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654

In, 2017, Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Database, Ann Surg Oncol, 24, 3683, 10.1245/s10434-017-6078-x

Gómez-Martin, 2012, HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer, J Clin Pathol, 65, 751, 10.1136/jclinpath-2012-200774

Van Cutsem, 2015, Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study, Ann Oncol, 26, 149, 10.1093/annonc/mdu496

Wilke, 2014, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, Lancet Oncol, 15, 1224, 10.1016/S1470-2045(14)70420-6

Weber, 2004, Imaging of esophageal and gastric cancer, Semin Oncol, 31, 530, 10.1053/j.seminoncol.2004.04.016

Enzinger, 2005, A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma, Dig Dis Sci, 50, 2218, 10.1007/s10620-005-3038-2

Ly, 2010, A systematic review of methods to palliate malignant gastric outlet obstruction, Surg Endosc, 24, 290, 10.1007/s00464-009-0577-1

Al-Batran, 2004, Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer, J Clin Oncol, 22, 658, 10.1200/JCO.2004.07.042

Siewert, 1996, Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection, Dis Esophagus, 9, 173

Rüdiger Siewert, 2000, Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients, Ann Surg, 232, 353, 10.1097/00000658-200009000-00007

Fuchs, 2003, Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer, J Clin Oncol, 21, 807, 10.1200/JCO.2003.08.058

Ajani, 2002, CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study, Cancer, 94, 641, 10.1002/cncr.10279

Kang, 2009, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 20, 666, 10.1093/annonc/mdn717

Brell, 2009, A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma, Cancer Chemother Pharmacol, 63, 851, 10.1007/s00280-008-0807-6

Shitara, 2020, Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, N Engl J Med, 382, 2419, 10.1056/NEJMoa2004413

Hong, 2004, A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer, Ann Oncol, 15, 1344, 10.1093/annonc/mdh343

Lim, 2007, Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?, J Surg Oncol, 95, 118, 10.1002/jso.20328

Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200/JCO.1984.2.3.187

Lindsay, 2004, Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass, Aliment Pharmacol Ther, 19, 901, 10.1111/j.1365-2036.2004.01896.x

Fuchs, 2019, Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 420, 10.1016/S1470-2045(18)30791-5

Kunz, 2012, HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment, Appl Immunohistochem Mol Morphol, 20, 13, 10.1097/PAI.0b013e31821c821c

Bentrem, 2005, The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection, Ann Surg Oncol, 12, 347, 10.1245/ASO.2005.03.065

Gómez-Martin, 2012, HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer, J Clin Pathol, 65, 751, 10.1136/jclinpath-2012-200774

Gadgeel, 2003, Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer, Am J Clin Oncol, 26, 37, 10.1097/00000421-200302000-00008

Kang, 2012, Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone, J Clin Oncol, 30, 1513, 10.1200/JCO.2011.39.4585

Ryan, 1998, Performing radiologic gastrostomy or gastrojejunostomy in patients with malignant ascites, AJR Am J Roentgenol, 171, 1003, 10.2214/ajr.171.4.9762985

Enzinger, 2009, Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer, Ann Oncol, 20, 475, 10.1093/annonc/mdn658

Doebele, 2020, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 271, 10.1016/S1470-2045(19)30691-6